Actively Recruiting
Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda
Led by University of Rochester · Updated on 2026-01-12
11100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Rochester
Lead Sponsor
L
Lira University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to understand the burden, causes, diagnosis, treatment, and prevention of meningitis in northern Uganda. The study will collect detailed information to identify gaps in care and support routine vaccination for bacterial meningitis and improved screening guidelines for cryptococcal meningitis among HIV-positive patients. The University of Rochester sponsors this effort to improve meningitis care and outcomes in this region. Participants include 1100 patients admitted with meningitis symptoms at Lira Regional Referral Hospital and 10,000 HIV-positive patients screened for cryptococcal antigenemia. Modern diagnostic tests such as cryptococcal antigen lateral flow assay, Pastorex antigen agglutination assay, and Biofire PCR will be used to detect infectious agents and evaluate meningitis causes and risks. During the study, participants will undergo clinical assessments and diagnostic testing. Researchers will monitor deaths during hospitalization and up to 24 months after admission, as well as track cryptococcal antigen-positive cases and development of overt cryptococcal meningitis. The study will assess outcomes over two years, aiming to improve meningitis prevention strategies and care in Uganda.
CONDITIONS
Brief Title
Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of any age with meningitis or meningitis symptoms admitted to Lira Regional Referral Hospital
- HIV-positive patients presenting to LRRH, LRRH HIV Clinic, or nearby outpatient clinics
- Patients willing to undergo diagnostic testing for meningitis
- Participants presenting with symptoms such as headache, fever, confusion, photophobia, neck stiffness, seizure, or bulging fontanel
You will not qualify if you...
- Patients without meningitis after evaluation or with alternative diagnoses explaining symptoms
- HIV-negative patients without signs or symptoms of meningitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) at outpatient clinics or hospital admission
Duration - Up to 2 weeks during hospitalization
Participants undergo diagnostic testing for meningitis using rapid molecular tests based on clinical assessment and HIV status.
Diagnostic tests performed during hospitalization
Duration - Up to 24 months after hospital admission
Participants are monitored for outcomes including survival and development of cryptococcal meningitis after hospital discharge.
Follow-up visits and assessments up to 24 months
Trial Site Locations
Total: 1 location
1
Lira Regional Referral Hospital
Lira, Uganda, 224180000
Actively Recruiting
Research Team
P
Paul Bohjanen, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here